Genfit S.A. (GNFT)
NASDAQ: GNFT · Real-Time Price · USD
5.51
0.00 (0.00%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Company Description

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.

The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis.

It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.

The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA.

The company was incorporated in 1999 and is headquartered in Loos, France.

Genfit S.A.
Genfit logo
Country France
Founded 1999
IPO Date Mar 27, 2019
Industry Biotechnology
Sector Healthcare
Employees 159
CEO M. Prigent

Contact Details

Address:
Parc EurasantE, 885, avenue EugEne AvinEe
Loos, 59120
France
Phone 33 3 20 16 40 00
Website genfit.com

Stock Details

Ticker Symbol GNFT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency EUR
IPO Price $22.00
CIK Code 0001757064
CUSIP Number 372279109
ISIN Number US3722791098
SIC Code 2836

Key Executives

Name Position
M. Pascal Prigent Chief Executive Officer
Jean-Francois Mouney Co-Founder and Chairman of the Board
Prof. Bart Staels Co-Founder and Chairman of the Scientific Advisory Board
Thomas Baetz Chief Financial Officer
Pascal Caisey Chief Operating Officer
Dr. Meriam Kabbaj Ph.D. Chief Technology Officer
Dr. Dean W. Hum Ph.D. Chief Scientific Officer
Jean-Christophe Marcoux Chief Corporate Affairs Officer, Head of Investor Relations and Head of ESG
Laurent Lannoo Corporate Secretary and Director of Legal Affairs
Stefanie Magner J.D. Chief Compliance Officer and Executive Vice President of International Legal Affairs

Latest SEC Filings

Date Type Title
Sep 23, 2024 6-K Report of foreign issuer
Sep 19, 2024 6-K Report of foreign issuer
Sep 19, 2024 6-K Report of foreign issuer
Jul 26, 2024 6-K Report of foreign issuer
Jul 9, 2024 6-K Report of foreign issuer
Jun 17, 2024 6-K Report of foreign issuer
Jun 11, 2024 6-K Report of foreign issuer
May 29, 2024 6-K Report of foreign issuer
May 22, 2024 6-K Report of foreign issuer
May 14, 2024 6-K Report of foreign issuer